Table 5.
Scenario analysis cost and outcomes when considering direct effects only
| Outcome | PCV13 | PCV10 | Difference (PCV13 – PCV10) |
|---|---|---|---|
| Total life-years |
605,587,157 |
605,586,870 |
287.45 |
| Total QALYs |
543,278,132 |
543,264,303 |
257.70 |
| Annual number of cases | |||
| Myringotomy |
1,906 |
1,918 |
−11.0 |
| Neurological impairment |
35.7 |
35.8 |
−0.1 |
| Hearing loss |
66.3 |
66.5 |
−0.2 |
| Death |
10,466.50 |
10,480.47 |
−14.0 |
| Annual direct medical costs |
$1,312,418,621 |
$1,318,177,638 |
–$5,759,017 |
| Cost per QALY | PCV13 dominates PCV10 | ||
PCV10 10-valent pneumococcal conjugate vaccine; PCV13 13-valent pneumococcal conjugate vaccine; QALY quality-adjusted life-year.